Repare Therapeutics’ Post

LHS is proud to work with Panavance Therapeutics Inc. in the fight against ovarian cancer. With approximately 20,000 new cases diagnosed annually in the U.S., the need for effective treatments is critical. Panavance’s lead program, misetionamide (GP-2250), is a tumor cell-selective small molecule with broad anti-cancer activity. The company plans to pursue a Phase 1/2 proof-of-concept study targeting platinum-resistant ovarian cancer. As we observe Ovarian Cancer Awareness Month, let’s raise awareness of this devastating disease and encourage women to be vigilant about symptoms and proactive in advocating for their health. #ovariancancer #ovariancancerawarenessmonth

Did you know? Liver cancer incidence rates have more than tripled since 1980? The American Cancer Society estimates about 41,630 adults in the United States will be diagnosed with primary #livercancer in 2024. Through our advancement in biomarker research and testing, Fujifilm is continuing to raise awareness around early detection of Hepatocellular carcinoma (HCC) - the most common type of primary liver cancer. Learn more about our serum biomarkers and the work our In Vitro Diagnostics division is doing here: https://brnw.ch/21wOeCL #LiverCancerAwarenessMonth

Access the widely used MB49 murine bladder carcinoma cell line on CancerTools.org (CancerToolsOrg). This line is one of the most established in vitro and in vivo models of urothelial bladder cancer with metastatic potential. It shares pivotal characteristics with human bladder cancer and has been widely used for more than 45 years after its original publication by Cancer Research UK (CRUK) researcher, Leonard Franks. Our MB49 derivatives include #MB49-luc cell line, offering an in vivo readout for tumour take, growth, and reduction.  Click here to access the MB49 cell lines: https://hubs.la/Q02vgph-0 #lifesciences #mb49 #celllines #oncologyresearch #mousebladder #carcinoma #cancerresearch #genomics #researchtools #bladdercancer #depositedbyscientists #acceleratecancerresearch

Have you read the latest Australian Breast Cancer Research Review Issue? In Issue 61 we cover an article on digital histological biomarker for invasive breast cancer prognosis, along with many other amazing studies!!! Read your copy HERE: https://lnkd.in/gurftX_a #breastcancerawareness #australia #research #review #prognosis

🔬We’re thrilled to announce the results of the TOPGEAR trial on gastric and gastroesophageal junction adenocarcinoma. The study showed that the addition of preoperative chemoradiotherapy did not improve progression-free survival or overall survival compared to perioperative chemotherapy alone. This breakthrough will impact clinical practice worldwide. Learn more here: https://lnkd.in/ggs3X8HQ Karin Haustermans, Florian Lordick, NHMRC Clinical Trials Centre, Canadian Cancer Trials Group, Trans Tasman Radiation Oncology Group (TROG Cancer Research), GI Cancer Institute & Australasian Gastro-Intestinal Trials Group, NEJM Group #CancerResearch #ClinicalTrials #GastricCancer #Oncology #Adenocarcinoma #ESMO24

The Masters in Thoracic Oncology Summit | MaTOS is a 3-day meeting, presented in significant distinct sessions by key thoracic oncology experts. This summit will address and discuss the current challenges and future directions in the lung cancer space. Through open discussions we will have the opportunity to analyze the latest discoveries in genetics and epigenomics in lung cancer, including diagnosis, minimal residual disease (MRD), monitoring for recurrence, and assessment of therapeutic success with targeted therapy and immunotherapy. #lungcancer #lcsm

NEW from #AACR2024 | COMPASSION-15: #cadonilimab in advanced #gastriccancers 🇺🇸 🎥 Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, presents the results of the randomized, double-blind, Phase III COMPASSION-15 trial (NCT05008783) 🔦 The study showed that administering #cadonilimab, an anti-PD-L1 and CTLA-4 #bispecificantibody, resulted in a promising response rate in patients with unresectable locally advanced or #metastaticgastriccancer These findings suggest that the dual PD-L1 and CTLA4 blockade can be targeted safely in combination with #chemotherapy Learn more 👉 https://lnkd.in/eE8CQjdn #VJOncology #Oncologynews

The American Association for Cancer Research Project GENIE registry is among the largest fully public cancer genomic data set.   This past month saw the latest public data release, which can be accessed via our Synapse platform. This takes the total number of public data releases to 15, with nearly 200,000 samples in the registry from over 170,000 patients.   Through transparent data sharing and reuse, this initiative is advancing precision oncology medicines and powering clinical decision-making for some of the hardest-to-treat cancers. Register for Synapse today and explore the latest data release: https://lnkd.in/guBvp_c7 #projectgenie #AACR #cancer #genomics #oncology #opendata

September is Ovarian Cancer Awareness Month, a time to educate and heighten awareness about #ovariancancer. Ovarian cancer is the 8th most common cancer and the 5th leading cause of cancer death in women.   Panavance is developing misetionamide (GP-2250) for ovarian cancer.   We recently announced foundational preclinical results of misetionamide in ovarian cancer which demonstrated profound effects on tumor metabolism, anti-angiogenic activity, protein synthesis, and DNA transcription.   Learn more about our work here: https://lnkd.in/erN-j8Ep   #ovariancancerawarenessmonth #oncology

What are the main types of lung cancer? Which cell lines are best for your lung cancer research? Understanding the nuances of these classifications is crucial for researchers, especially when selecting the appropriate cell lines for their studies. Cell lines such as A549, H1975, and H460 play pivotal roles in lung cancer research, each offering unique insights into tumor biology, metastasis, drug resistance, and more. At #Pricella, we support your lung cancer research with our comprehensive range of cell culture media, reagents, and custom solutions to tailor our products to your unique research requirements, helping you achieve breakthroughs in understanding and treating lung cancer. 🔗 https://lnkd.in/ggMG3vwN #LungCancer #CancerResearch #NSCLC #SCLC #CellCulture